Abstract
Objective: MicroRNAs (miRs) are noncoding, single-stranded regulatory RNA molecules involved in the posttranscriptional regulation of gene expression. They control the development and maintenance of the diverse cellular processes including proliferation, differentiation, motility and apoptosis. Expression of miRs is tissue-specific and each alteration of the tissue miR profile is associated with a distinct disease status. Study Design: We reviewed the literature on the expression of miRs in thyroid tumors, focusing on methodology and diagnostic and prognostic output. Separately, we analyzed 11 studies on miR profiles in thyroid cytological material. Results: Numerous studies have evaluated the miR profiles of thyroid tumors in an attempt to find a possible diagnostic and prognostic role. Both downregulation and upregulation of numerous miRs was found, but differences between the surgical pathology specimens and corresponding fine-needle aspirates in the expression of the same miRs were also reported. Conclusions: The results from surgically resected material cannot be extrapolated into preoperative use without validation. For diagnostic use, the strong overlap between follicular adenoma and follicular carcinoma miR profiles is challenging. In summary, miR-221 and miR-222 are consistently upregulated in different types of thyroid carcinomas and might be used as markers of malignancy.
Journal Section:
Editor's choice
References
1.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658-665.
[PubMed]
2.
Kholová I, Ludvíková M: Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage? Acta Cytol 2014;58:319-329.
[PubMed]
3.
Bongiovanni M, Krane JF, Cibas ES, Faquin WC: The atypical thyroid fine-needle aspiration: past, present, and future. Cancer Cytopathol 2012;120:73-86.
[PubMed]
4.
Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-580.
[PubMed]
5.
Gilfillan CP: Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J Surg 2010;80:33-40.
[PubMed]
6.
Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-1069.
[PubMed]
7.
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-2098.
[PubMed]
8.
Catalano MG, Fortunati N, Boccuzzi G: Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne) 2012;3:40.
[PubMed]
9.
Faam B, Ghaffari MA, Ghadiri A, Azizi F: Epigenetic modifications in human thyroid cancer. Biomed Rep 2015;3:3-8.
[PubMed]
10.
Russo D, Damante G, Puxeddu E, Durante C, Filetti S: Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 2011;46:R73-R81.
[PubMed]
11.
Vu-Phan D, Koenig RJ: Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol 2014;386:55-66.
[PubMed]
12.
Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
[PubMed]
13.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
[PubMed]
14.
Zhou X, Yang PC: MicroRNA: a small molecule with a big biological impact. MicroRNA 2012;1:1.
[PubMed]
15.
Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13:3191-3197.
[PubMed]
16.
Ross JS, Carlson JA, Brock G: MiRNA: the new gene silencer. Am J Clin Pathol 2007;128:830-836.
[PubMed]
17.
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-1910.
[PubMed]
18.
Kalfert D, Pesta M, Kulda V, Topolcan O, Ryska A, Celakovsky P, Laco J, Ludvikova M: MicroRNA profile in site-specific head and neck squamous cell cancer. Anticancer Res 2015;35:2455-2463.
[PubMed]
19.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
[PubMed]
20.
Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D, Wang K: Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 2010;16:2170-2180.
[PubMed]
21.
Cheng G: Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2015;81:75-93.
[PubMed]
22.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
[PubMed]
23.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
[PubMed]
24.
Marini F, Luzi E, Brandi ML: MicroRNA role in thyroid cancer development. J Thyroid Res 2011;2011:407123.
[PubMed]
25.
Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10:389-402.
[PubMed]
26.
Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA: Regulatory mechanisms of microRNA involvement in cancer. Expert Opin Biol Ther 2007;7:1009-1019.
[PubMed]
27.
Negrini M, Ferracin M, Sabbioni S, Croce CM: MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007;120:1833-1840.
[PubMed]
28.
Forte S, La Rosa C, Pecce V, Rosignolo F, Memeo L: The role of microRNAs in thyroid carcinomas. Anticancer Res 2015;35:2037-2047.
[PubMed]
29.
Yuan ZM, Yang ZL, Zheng Q: Deregulation of microRNA expression in thyroid tumors. J Zhejiang Univ Sci B 2014;15:212-224.
[PubMed]
30.
Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cina D, Libra M: MicroRNAs and thyroid cancer: biological and clinical significance (review). Int J Mol Med 2012;30:991-999.
[PubMed]
31.
Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C: A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91:3584-3591.
[PubMed]
32.
Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH, Kebebew E: MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2012;118:3426-3432.
[PubMed]
33.
Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA, Kebebew E: Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol 2011;18:3443-3452.
[PubMed]
34.
Stokowy T, Wojtas B, Krajewska J, Stobiecka E, Dralle H, Musholt T, Hauptmann S, Lange D, Hegedus L, Jarzab B, Krohn K, Paschke R, Eszlinger M: A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. Mol Cell Endocrinol 2015;399:43-49.
[PubMed]
35.
Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd, Scognamiglio T: MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008;21:1139-1146.
[PubMed]
36.
Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sorensen C, Kiss K, Bennedbaek FN, Nielsen FC: Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol 2012;48:11-23.
[PubMed]
37.
Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, Nikiforov YE, Nikiforova MN: MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab 2013;98:E1-E7.
[PubMed]
38.
Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG, Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer 2013;119:4358-4365.
[PubMed]
39.
Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN: Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid 2013;23:1383-1389.
[PubMed]
40.
Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN: MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol 2014;52:181-189.
[PubMed]
41.
Fuziwara CS, Kimura ET: MicroRNA deregulation in anaplastic thyroid cancer biology. Int J Endocrinol 2014;2014:743450.
[PubMed]
42.
Hebrant A, Floor S, Saiselet M, Antoniou A, Desbuleux A, Snyers B, La C, de Saint Aubain N, Leteurtre E, Andry G, Maenhaut C: MiRNA expression in anaplastic thyroid carcinomas. PLoS One 2014;9:e103871.
[PubMed]
43.
Williams ED: Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 2000;8:181-183.
[PubMed]
44.
Lassalle S, Hofman V, Ilie M, Bonnetaud C, Puissegur MP, Brest P, Loubatier C, Guevara N, Bordone O, Cardinaud B, Lebrigand K, Rios G, Santini J, Franc B, Mari B, Al Ghuzlan A, Vielh P, Barbry P, Hofman P: Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Endocr Relat Cancer 2011;18:579-594.
[PubMed]
45.
Mazeh H, Levy Y, Mizrahi I, Appelbaum L, Ilyayev N, Halle D, Freund HR, Nissan A: Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Surg Res 2013;180:216-221.
[PubMed]
46.
Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A, Niccolai F, Molinaro A, Di Coscio G, Pinchera A, Vitti P, Tonacchera M: MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol 2012;167:393-400.
[PubMed]
47.
Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A, Kloos RT, He H: MicroRNA signature in thyroid fine needle aspiration cytology applied to ‘atypia of undetermined significance' cases. Thyroid 2012;22:9-16.
[PubMed]
48.
Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O, Fahey TJ 3rd: A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012;18:2032-2038.
[PubMed]
49.
Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA, Kebebew E: Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid 2012;22:285-291.
[PubMed]
50.
Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE: MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-1608.
[PubMed]
51.
Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A: Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 2011;21:111-118.
[PubMed]
52.
Fassina A, Cappellesso R, Simonato F, Siri M, Ventura L, Tosato F, Busund LT, Pelizzo MR, Fassan M: A 4-microRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. Cancer Cytopathol 2014;122:274-281.
[PubMed]
53.
Petriella D, Galetta D, Rubini V, Savino E, Paradiso A, Simone G, Tommasi S: Molecular profiling of Thin-Prep FNA samples in assisting clinical management of non-small-cell lung cancer. Mol Biotechnol 2013;54:913-919.
[PubMed]
54.
Kholová I, Ryska A, Ludvíková M, Cáp J, Pecen L: Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 2003;14:27-31.
[PubMed]
55.
Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, Nikiforova MN: MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011;18:2035-2041.
[PubMed]
56.
Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY, Liu RT: Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:E196-E205.
[PubMed]
57.
Li L, Lv B, Chen B, Guan M, Sun Y, Li H, Zhang B, Ding C, He S, Zeng Q: Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. Biochem Biophys Res Commun 2015;462:314-321.
[PubMed]
58.
Menon MP, Khan A: Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol 2009;62:978-985.
[PubMed]
59.
Sondermann A, Andreghetto FM, Moulatlet AC, da Silva Victor E, de Castro MG, Nunes FD, Brandao LG, Severino P: MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. Clin Exp Metastasis 2015;32:521-530.
[PubMed]
60.
Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC, Liu RT: MiR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(v600e) mutation. Thyroid 2010;20:489-494.
[PubMed]
61.
Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, Smallridge RC, Quezado MM, Kebebew E: MiR-30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Res 2015;75:367-377.
[PubMed]
62.
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, Zheng XL, Xiao H: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2012;97:2084-2092.
[PubMed]
63.
Zhang Y, Zhong Q, Chen X, Fang J, Huang Z: Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples. Tumour Biol 2014;35:9343-9353.
[PubMed]
64.
Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY: MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2015. doi:10.1111/cen.12696.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
